VEA
ITOS

Virtus ETF Advisers’s iTeos Therapeutics ITOS Stock Holding History

Virtus ETF Advisers’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,948
Closed -$68.7K – 611
2024
Q4 		$68.7K Buy
8,948
+3,293
+58% +$28.3K 0.03% 389
2024
Q3 		$57.7K Buy
5,655
+101
+2% +$1.54K 0.03% 438
2024
Q2 		$82.4K Sell
5,554
-2,492
-31% -$35.7K 0.04% 393
2024
Q1 		$110K Sell
8,046
-550
-6% -$5.99K 0.06% 353
2023
Q4 		$94.1K Buy
8,596
+1,530
+22% +$15.2K 0.06% 388
2023
Q3 		$77.4K Sell
7,066
-707
-9% -$9.04K 0.05% 366
2023
Q2 		$103K Buy
7,773
+2,991
+63% +$42.6K 0.06% 368
2023
Q1 		$65.1K Sell
4,782
-1,838
-28% -$32.9K 0.04% 412
2022
Q4 		$129K Buy
6,620
+792
+14% +$15.5K 0.07% 389
2022
Q3 		$111K Buy
5,828
+38
+0.7% +$875 0.04% 409
2022
Q2 		$119K Buy
5,790
+1,629
+39% +$38.7K 0.04% 386
2022
Q1 		$134K Sell
4,161
-251
-6% -$9.12K 0.06% 244
2021
Q4 		$205K Sell
4,412
-3,319
-43% -$110K 0.08% 200
2021
Q3 		$209K Sell
7,731
-403
-5% -$10.5K 0.09% 260
2021
Q2 		$209K Sell
8,134
-1,958
-19% -$46.7K 0.09% 315
2021
Q1 		$345K Buy
10,092
+176
+2% +$6.36K 0.15% 210
2020
Q4 		$335K Buy
+9,916
New +$263K 0.14% 181

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Virtus ETF Advisers's ITOS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of iTeos Therapeutics (ITOS) in Q1 2025, closing a stake of 8,948 shares — an estimated $68.7K sold.

Virtus ETF Advisers first reported a position in ITOS in Q4 2020 and held it in 17 quarters. The position peaked at $345K in Q1 2021. 131 funds tracked by Wall St. Rank hold ITOS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining iTeos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 8,948 iTeos Therapeutics shares in Q1 2025, an estimated $68.7K.
  • Virtus ETF Advisers first reported a position in iTeos Therapeutics in Q4 2020 and held it in 17 quarters.
  • Virtus ETF Advisers's iTeos Therapeutics position peaked at $345K in Q1 2021.
  • 131 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.